18th Nov 2013 10:03
LONDON (Alliance News) - Drug developer Silence Therapeutics PLC Monday said it plans to carry out a second study with the University of Birmingham for its Atu027 cancer treatment.
The study will test the safety of the drug in combination with cisplatin, 5-FU and cetuximab, concentrating on first-line and second-line patients with recurrent or metastatic head and neck squamous cell carcinoma.
The study hopes to further determine whether Atu027's presumed ability to stop cancerous activity spreading would work synergistically with the anti-neoplastic activity of traditional oncology drugs.
The trial is in the process of being adopted on to the National Cancer Research Institute's head and neck portfolio.
Silence Therapeutics also said Executive Chairman Jerry Randall has stepped down. Simon Sturge, currently a non-executive director of the company, will replace him in non-executive capacity.
The stock was trading at 266.75 pence Monday morning, up 4.25 pence or 1.6%.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L